A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

PHASE3CompletedINTERVENTIONAL

Enrollment

454

Participants

Timeline

Start Date

March 19, 2003

Primary Completion Date

March 15, 2004

Study Completion Date

March 15, 2004

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

MK0217, alendronate sodium/Duration of Treatment: 6 months

DRUG

Comparator: placebo / Duration of Treatment: 6 months

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00092027 - A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219) | Biotech Hunter | Biotech Hunter